BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalinowski A, Liliental J, Anker LA, Linkovski O, Culbertson C, Hall JN, Pattni R, Sabatti C, Noordsy D, Hallmayer JF, Mellins ED, Ballon JS, O'Hara R, Levinson DF, Urban AE. Increased activation product of complement 4 protein in plasma of individuals with schizophrenia. Transl Psychiatry 2021;11:486. [PMID: 34552056 DOI: 10.1038/s41398-021-01583-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022. [PMID: 35831706 DOI: 10.1007/s40263-022-00935-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hatzimanolis A, Foteli S, Stefanatou P, Ntigrintaki AA, Ralli I, Kollias K, Nikolaou C, Gazouli M, Stefanis NC. Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35532796 DOI: 10.1007/s00406-022-01409-5] [Reference Citation Analysis]
3 Dienel SJ, Schoonover KE, Lewis DA. Cognitive Dysfunction and Prefrontal Cortical Circuit Alterations in Schizophrenia: Developmental Trajectories. Biological Psychiatry 2022. [DOI: 10.1016/j.biopsych.2022.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]